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Abstract 
One of many new targets when looking for anti-cancer treatment is the polyamine pathway, which is 
essential in cell proliferation, gene regulation and cell death. A way to intervene with this pathway is 
to use compounds called polyamine analogues. Depletion in the intracellular polyamine pools results 
in decrease in cell proliferation, something that is desirable in cancer treatment. In this study the effect 
of two different polyamine analogues, PG11144 and PG11047 (10 µM concentration), on the prostate 
cancer cell line LNCap-FGC was investigated in both normoxia (21% O2) and hypoxia (1% O2) to 
better mimic the actual conditions in the tumor. Tumors often contain oxygen-deprived areas, which 
have been reported to be involved in the development of malignancy. When the cells were cultured in 
hypoxia, the colony forming efficiency in soft agar increased 100-fold compared to culturing in 
normoxia, indicating an increase in malignancy. PG11144 or PG11047 treatment decreased the colony 
formation efficiency of cells grown in hypoxia. The expression of β-catenin, a marker of malignancy, 
decreased in PG11144- or PG11047-treated cells grown in normoxia and hypoxia, with PG11144 
being the most effective. Treatment with either compound reduced cell proliferation, especially in 
normoxia. Altogether, the data show promising anticancer activities of both compounds in LNCap-
FGC cells grown in normoxia and hypoxia. 
 
Introduction 
Prostate cancer is the most common form of 
cancer in Swedish men, representing 32.2% of 
all reported male cancer cases in 2011 (1). It is 
normally treated with surgery, radiation therapy 
or androgen ablation, and the outcome is 
generally good in localized tumors (2). Prostate 
cancer cells are initially dependent on androgens 
for growth and progression, but over time, the 
cells can develop androgen independency 
resulting in a more aggressive form of cancer. 
Among the patients with castration-resistant 
prostate cancer, 50-70% will develop bone 
metastasis, for which no effective treatment 
exists (3). For metastasis to occur, the epithelial 
cells need to change into mesenchymal cells in a 
process called epithelial-to-mesenchymal 
transition (EMT) (4). This is a well-known, 
essential process in normal embryonic 
development and in tissue repair, but it has also 
been shown to play an important role in cancer 
progression. EMT can be induced by several 
extracellular factors, including growth factors 
such as WNT, TGF-β, FGF, and EGF, and 
components of the extracellular matrix such as 
collagen and hyaluronic acid. Polyamines may 
also be involved in mediating EMT (5). The 
process involves down-regulation of the 
epithelial protein E-cadherin and up-regulation 
of the mesenchymal protein N-cadherin among 
others. It also involves up-regulation of vimentin 
and down-regulation of cytokeratin 18 (6-7). The 
mesenchymal phenotype is more invasive and is 
able to migrate and colonize new 
microenvironments (6). Once the cells reach the 
new site in the body they go through the reverse 
process of EMT, mesenchymal-to-epithelial 
transition (MET) and form the new tumor. 
     Studies have shown that EMT can be induced 
by a hypoxic environment (8, 9). In solid tumors 
the vascular system is often disorganized and 
variable (10). Insufficient blood supply leads to 
regions of hypoxia where the oxygen 
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consumption outweighs the oxygen supply.  Low 
oxygen pressure decreases the proliferation of 
most cells, but it can also enable them to 
transform and become more aggressive and 
develop drug-resistance. Different transcription 
factors that help the cells to cope with the 
stressful environment are activated. Over-
expression of the protein hypoxia-inducible 
factor-1α (HIF-1α) has been shown to be 
involved in EMT since increasing levels of HIF-
1α are associated with up-regulation of vimentin 
expression and down-regulation of E-cadherin 
(9). Hypoxia also selects for apoptosis resistant 
cells, such as cells that lack the tumor suppressor 
p53 (11). As soon as the transformed cells get 
access to the blood stream and receive oxygen 
and nutrients, for example if parts of the tumor 
are killed by treatment, they are able to spread 
and colonize new areas of the body (10). 
Hypoxia also selects for cancer stem cells. 
Cancer stem cells are also able to migrate and 
form tumors at new sites of the body, and they 
can regenerate the tumor after treatment or 
surgery. They are similar to normal stem cells in 
the aspect that they have a long life span, are 
resistant to apoptosis, can induce angiogenesis, 
have ability for self-renewal and differentiation, 
etc. (12). It has been shown that the residues of 
normal stem cells, e.g. stem cell residues in the 
bone marrow and in the brain, are hypoxic, and 
as soon as the stem cells are exposed to oxygen 
they start to differentiate (13). The same seems 
to occur for cancer stem cells. Hypoxia maintains 
their undifferentiated state, and can also modify 
the gene expression, resulting in stem-ness. It is 
therefore of great interest to find a way to kill 
these cells. 
     One interesting approach for treatment of 
cancer is to target the polyamine homeostasis. 
Polyamines are organic polycations that exist in 
all, so far studied, prokaryotic and eukaryotic 
cells. There are three naturally occurring 
polyamines, the diamine putrescine, the triamine 
spermidine, and the tetra-amine spermine (14). 
The polyamines are essential for growth, 
differentiation and cell death (15). Their positive 
charge makes it possible for them to bind to 
negatively charged macromolecules such as 
nucleic acids, phosphoproteins and 
phospholipids (16). They stabilize and stimulate 
the replication of DNA and are involved in the 
organization of chromatin. They regulate the 
activation of kinases in a number of growth-
related pathways in the cell, including the 
Ras/MAPK pathway, one of the best-defined 
pathways in cell proliferation. Through these 
pathways polyamines regulate multiple 
functions, such as transcription, translation, 
nucleic acid synthesis, centrosome positioning in 
mitosis, cytokinesis, modulation of ion channels, 
and membrane stability (15, 17-19).  
     The intracellular levels of polyamines are 
regulated by biosynthesis, uptake/excretion, and 
catabolism (14, 20). Polyamines are synthesized 
by the enzyme ornithine decarboxylase (ODC), 
which converts ornithine to putrescine. This is 
the rate-limiting step of polyamine biosynthesis. 
ODC is an enzyme with a very short half-life 
which is e.g. synthesized upon hormone 
stimulation. An over-production of ODC has 
been observed in numerous cancers, and ODC 
has been defined as an oncogene (21). Putrescine 
can in turn be converted into spermidine and 
spermine by spermidine synthase and spermine 
synthase by addition of one or two aminopropyl 
groups. The aminopropyl group donor in the 
reaction, decarboxylated S-adenosylmethionine, 
is formed by decarboxylation of S-
adenosylmethionine by the enzyme S-
adenosylmethionine decarboxylase (22). The 
uptake of polyamines is mediated by active 
transport (14) and is dependent on the pH and the 
extra- and intracellular polyamine levels. Many 
kinds of food contain high amounts of 
polyamines and by changing the diet in 
combination with ODC inhibiting treatments, 
such as 2-difluoromethylornithine, it has been 
possible to limit the growth of prostate cancer 
(23).  
     There is a strong correlation between 
polyamine accumulation and cancer (24, 25). 
High levels of polyamines can be observed in all 
hyperproliferative cells, but the high levels are 
extra prominent in cancer cells. This is due to a 
frequent dysfunction of the polyamine 
metabolism in most cancers. In normal cells, the 
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metabolic pathways are tightly regulated and 
polyamine levels remain low in non-proliferating 
cells and is stimulated when normal cells have to 
grow e.g. in tissue repair processes. It has also 
been suggested that increased levels of 
polyamines in cancer cells can be involved in 
EMT and contribute to malignancy (26). 
Targeting the polyamine functions and metabolic 
pathways has therefore been of great interest 
when searching for new cancer treatments.   One   
way   is   to   use   structurally similar 
compounds   called   polyamine   analogues.  The 
analogues are supposed to use the pathways and 
mechanisms originated for the natural 
polyamines without substituting their function 
(27). They also inhibit the biosynthesis and 
uptake of the naturally occurring polyamines and 
enhance the activity of the catabolic enzymes. 
Taken together this should deplete the polyamine 
pools in the cells resulting in growth-inhibition 
and cell death. It is also important that the 
analogues are more toxic for cancer cells than for 
normal cells. 
     In this study the effects of two different 
polyamine analogues, 3,8,13,18,23,28,33,43,48-
deca-aza-(trans-25)-pentacontene (PG11144, 
previously known as SL11144 and CGC11144) 
and [1N,12N]bis(ethyl)-cis-6,7-dehydrospermine 
(PG11047, previously known as SL11047 and 
CGC11047) (Fig. 1) on the androgen-dependent 
prostate cancer cell line LNCap-FGC were 
investigated. PG11047  is  a  bisethyl  spermine  
 
 
 
Figure 1. The molecular structures of the naturally 
occurring polyamines putrescine, spermidine and spermine, 
and the two polyamine analogues PG11047 and PG11144.  
(Ref. John Stegmayr)              
analogue   that   competes    with    the   natural 
polyamines and inhibits their normal functions 
(28). It is taken up by the polyamine transporter 
system and accumulates in the cell where it 
depletes the intracellular levels of all polyamines 
by feedback inhibition of enzymes involved in 
the polyamine biosynthesis. It also activates the  
enzymes spermidine/spermine N1-acetyl-
transferase (SSAT) and spermine oxidase 
(SMO), which catalyzes the catabolism of 
polyamines. The depletion of the intracellular 
polyamine pools results in decreased 
proliferation. It has also been suggested that it 
can induce MET and reduce the number of 
cancer stem cells in human breast cancer cell 
lines (29, 30). The compound is in phase II 
clinical trials for prostate cancer. PG11144 is a 
trans-decamine which has been shown to have 
high anti-proliferative properties and to cause 
apoptosis in both prostate and breast cancer cells 
(31, 32). It reduces the levels of all the three 
polyamines in the cell both by inhibiting 
polyamine biosynthetic enzymes and by 
increasing the activity of SSAT. PG11144 has 
been shown to inhibit lysine-specific 
demethylase-1 (LSD-1), an enzyme that is often 
highly expressed in cancer (33, 34). LSD-1 
catalyzes the demethylation of histone 3 at lysine 
4, a process that leads to epigenetic silencing of 
tumor suppressor genes. The catalytic domain of 
LSD-1 is more than 60 % similar to the catalytic 
domain of SMO, and PG11144 is structurally 
similar to the lysine tail of the histone. This 
makes it possible for the analogue to bind to and 
inhibit the enzyme.  
     The aim of this study was to investigate how 
PG11144 and PG11047 effected cell 
proliferation of LNCap-FGC androgen 
dependent prostate cancer cells, to see if they 
caused cell death and to see if they had any 
impact on the malignancy of the cells by looking 
at the stem cell population, the colony forming 
efficiency in soft agar, and EMT versus MET 
markers. Of importance was also to investigate 
how the effects differed between hypoxia (1% 
O2) and normoxia (21% O2). LNCap-FGC 
prostate cancer cells were cultured in either 
normoxia or hypoxia in absence or presence of 
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either PG11144 or PG11047. The results show 
that treatment with PG11144 was more effective 
than treatment with PG11047 in both normoxia 
and hypoxia, but the effect was more prominent 
in normoxia. The colony forming efficiency of 
cells grown in normoxia was very low and 
colonies were only found in control. When cells 
were grown in hypoxia, the colony forming 
efficiency was greatly increased. Cultivation in 
hypoxia increased the expression of the EMT 
marker vimentin, but surprisingly it also 
increased the expression of the MET marker 
cytokeratin 18. However, both PG11144 and 
PG11047 treatment of cells in hypoxia resulted 
in a decreased colony formation. Treatment with 
both compounds reduced the expression β-
catenin. Thus, both PG11144 and PG11047 
proved to be inhibitory in both normoxia and 
hypoxia. This is the second report of an effect of 
the compounds on prostate cancer cells in 
hypoxia (35). 
 
Material and methods 
Materials 
RPMI-1640 medium was purchased from 
Biochrome, Berlin, Germany. Fetal bovine serum 
(FBS), non-essential amino acids, 
penicillin/streptomycin, Nonidet NP-40, 
NuSieve® GTG® agarose and phosphate-
buffered saline (PBS) tablets were purchased 
from VWR, Lund, Sweden. RPMI-1640 Medium 
Dutch Modification, Accutase® solution, 
propidium iodide (PI), TWEEN® 20, 
ribonuclease A, 2-mercaptoethanol, 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT), bovine serum albumin (BSA), 
agar, and sodium dodecyl sulfate (SDS) were 
purchased from Sigma-Aldrich, Stockholm, 
Sweden. Trypsin was purchased from OneMed 
Sverige AB, Gothenburg, Sweden. Tissue culture 
plastics were purchased from Nunc, Roskilde, 
Denmark. NuPAGE® 4-12% Bis-Tris 1.0 mm 10 
well gels, NuPAGE® MOPS SDS Running 
Buffer (20X), NuPAGE® Antioxidant, 
MagicMarkTM XP Western Standard, SeeBlue® 
Pre-Stained Standard (1X) and iBlot® Gel 
Transfer Stacks (Nitrocellulose, Regular), and 
AlexaFluor® 594 were purchased from 
Invitrogen Corporation, Carlsbad, CA, USA. 
Enhanced Chemiluminescence (ECL) Advanced 
Western Blotting Detection kit was purchased 
from GE Healthcare, Buckinghamshire, UK. 
Polyclonal swine anti-rabbit and goat anti-mouse 
immunoglobulins/HRP for Western Blot were 
purchased from Dako, Glostrup, Denmark. 
MEBM Basal medium (CC-3151 and CC-4136 
kit) were purchased from Lonza, Basel, 
Switzerland. B27 supplement was purchased 
from Life Technologies, Carlsbad, CA, USA. 
Basic fibroblast growth factor (bFGF) was 
purchased from R & D systems, Minneapolis, 
Minnesota, USA. Dimethyl sulfoxide (DMSO) 
was purchased from Merck KGaA, Damstadt, 
Germany. Primary antibodies used for Western 
Blot against human H3K4me2, LSD-1, and 
active β-catenin were purchased from Millipore, 
Bedford, MA, USA. Primary antibodies against 
human β-actin, GAPDH, poly (ADP) 
polymerase, caspase 3, vimentin, E-cadherin, and 
cytokeratin 18 were purchased from Abcam, 
Cambridge, UK. Primary antibodies against Bcl-
2 and p53 used for Western Blot, and antibodies 
against human CD24 and CD44, and Isotype 
used for stem cell flow cytometry were 
purchased from BD Biosciences, Stockholm, 
Sweden. Anti-γ-H2AX antibody was purchased 
from Cell Signaling Technology, Inc, Boston, 
MA, USA. Antibody against human HIF-1α was 
purchased from Novus Biologicals, Littleton, 
CO, USA. Antibody against human CD29 used 
for stem cell flow cytometry was purchased from 
Nordic BioSite. Bromophenol blue was 
purchased from ICN Biomedicals, INC, Irvine, 
CA, USA.  
 
Cell culturing  
All the experiments were performed on the 
human prostate cancer cell line LNCap-FGC, 
which was purchased from American Tissue 
Culture Collection (Manassas, VA, USA). The 
cells were grown as a monolayer culture. The 
cells cultured under normoxic conditions (21% 
O2) were grown in RPMI-1640 medium 
supplemented with 10% FBS, 100 U/ml 
penicillin, 100 µg/ml streptomycin and 1 mM 
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non-essential amino acids, and kept in a 
humidified incubator with 5% CO2 in normal air 
at 37°C. The cells were passaged once a week by 
harvesting with trypsin followed by reseeding at 
a density of 27 000 cells/cm2. Cells cultured 
under hypoxic conditions (1% O2) were grown in 
RPMI-1640 Dutch Modification medium 
supplemented with 10% FBS, 100 U/ml 
penicillin, 100 µg/ml streptomycin and 1 mM 
non-essential amino acids (hypoxia medium). 
These cells were kept in a humidified Whitley 
H35 hypoxiastation (Don Whitley Scientific, 
West Yorkshire, UK), with 5% CO2, 1% O2, and 
94% N2 at 37°C. 
     For the experiments, cells were seeded at a 
density of 20 000 cells/cm2 unless otherwise 
stated. The cells were harvested using trypsin 
solution (0.05% in 1 mM EDTA) unless 
otherwise stated. The compounds were added 24 
hours after seeding in all the experiments. The 
compounds were added to concentrations of 10 
µM if not stated differently. 
     Stock solutions of 4 mM of both PG11144 
and PG11047 in PBS were used in the 
experiments. Both the compounds were provided 
by Progen Pharmaceuticals (Palo Alto, CA, 
USA). The solutions were stored at -20 °C. 
 
Dose-response assay 
Cells were harvested by trypsinization, counted 
in a hemocytometer and thereafter re-suspended 
to a final concentration of 33 000 cells/ml. The 
cell suspension was added to 96-well plates in 
aliquots of 180 µl, containing 6000 cells, per 
well. The cells were incubated under normoxic 
conditions for 24 hours. PG11144 and PG11047 
were diluted in sterile PBS and added in aliquots 
of 20 µl to obtain final concentrations of 0.01, 
0.1, 0.5, 1, 5, 10, 50, and 100 µM. Sterile PBS 
was used as control. Cells seeded for culturing in 
hypoxia were placed under hypoxic conditions 
and the medium was replaced with hypoxia 
medium prior to drug addition. The cytotoxicity 
was investigated after 48 and 72 hours of 
treatment. Twenty µl MTT solution (5 mg/ml in 
PBS) was added to each well followed by 
incubation for one hour in normoxia and 2 hours 
in hypoxia. The medium was removed and      
100 µl DMSO was added to each well. The 
plates were put on a shaker for 10 minutes before 
the absorbance was measured at 540 nm with a 
Labsystems iEMS Reader MF (Labsystems Oy, 
Helsinki, Finland) and the software DeltaSoft II 
v. 4.14 (Biometallics Inc., Princeton, NJ, USA). 
 
Cell proliferation assay 
Four hundred thousand cells were seeded in 5 ml 
of medium in a 25 cm2 tissue culture flask. 
PG11144 or PG11047 was added after 24 hours 
of incubation to final concentrations of 10 µM. 
The cells seeded for culturing in hypoxia were 
placed under hypoxic conditions after 24 hours. 
The medium was changed to hypoxia medium, 
before addition of compound.  
     The attached cells were harvested and 
collected by trypsinization 24 hours after 
seeding, and after 24, 48, and 72 hours of 
treatment. The cells were counted in a 
hemocytometer and total cell number 
determined. 
Flow cytometric analysis of cell death and cell 
cycle phase distribution 
Cells were harvested using trypsin 24 hours after 
seeding and after 24, 48, and 72 hours of 
treatment with 10 µM PG11144 or PG11047 in 
normoxia and hypoxia. Both detached (floating 
in the medium) and attached cells were collected, 
pelleted and re-suspended in ice cold 70% 
ethanol. The cells were stored at -20°C until 
further analysis.  
     The cells were washed once with 10 ml PBS 
and thereafter pelleted and re-suspended in PBS 
with 100 µg/ml propidium iodide, 0.6% NP-40, 
and 100 µg/ml ribonuclease-A. The samples 
were kept at 4°C over night. The samples were 
analyzed using a BD Accuri C6 flow cytometer, 
(BD Biosciences, San Jose, CA, USA).The cell 
cycle phase distribution and sub-G1 fraction were 
evaluated using the MultiCycle® 
software,(Phoenix Flow Systems, CA, USA). 
 
Western Blot analysis 
Cells were harvested by trypsinization after 48 
and 72 hours of treatment in normoxia or 
hypoxia. Only attached cells were collected. The 
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cells were counted and thereafter pelleted. The 
pellets were dried and stored at -80°C until 
further analysis.  
     The pellets were suspended in sample buffer 
(62.5 mM Tris-HCl, pH 6.8, 20% glycerol, 2%  
sodium dodecyl sulfate, 5% β-mercaptoethanol) 
with addition of 0.1% NP-40, 5000 cells/µl. The 
samples were sonicated for 2x10 seconds, and 
boiled for 6 minutes. The samples were stored at 
-20°C until further use. Pre-cast polyacrylamide 
gels were loaded with aliquots equivalent to 
75000 cells per well. The gel electrophoresis was 
performed in a XCell Surelock™ Mini-Cell 
Electrophoresis system (Invitrogen). The gels 
were run at 150 V for 90 minutes and they were 
thereafter blotted using an iBlot Dry Blotting 
System (Invitrogen). The nitrocellulose 
membranes were washed in PBS with 0.05% 
TWEEN® 20 (PBT) for 15 minutes and then 
stored at -20°C until antibody staining. Prior to 
staining, the membranes were washed 4x15 
minutes in 50 ml PBT and then blocked with 10 
ml PBT with 50 mg/ml dry milk for 1-2 hours at 
room temperature. For analysis of 
phosphorylated proteins the membranes were 
blocked with 10 ml PBS with 50 mg/ml bovine 
serum albumin. They were thereafter stained 
with primary antibodies against H3K4me2,  
LSD-1, β-actin, GAPDH, PARP, caspase 3, Bcl-
2, p53, β-catenin, γH2Ax, vimentin, E-cadherin, 
cytokeratin 18, and HIF-1α diluted in 5 ml PBT 
with 50 mg/ml dry milk or bovine serum albumin 
and incubated for one hour at room temperature 
or overnight at 4°C. The membranes were 
washed with PBT once again and thereafter 
incubated with secondary antibody, diluted in 5 
ml PBT, for one hour in room temperature. The 
membranes were washed with PBT followed by 
exposure to ECL solution. To detect the protein 
bands, the ChemiDoc XRS system (Bio-Rad 
Inc., Hercules, CA, USA) was used. 
 
Colony forming efficiency in soft agar 
The cells were harvested using trypsin and 
counted after 72 hours of treatment with either 
10 µM PG11144 or PG11047, in either hypoxia 
or normoxia. MEBM basal medium containing 
hydrocortisone, insulin, epidermal growth factor  
(all from CC-4136 kit), B27 supplement, bFGF 
(20    ng/ml),    penicillin    (50    U/ml),    and  
streptomycin (50 µg/ml) was heated to 42°C. 
Agarose was added to the medium to a final 
concentration of 0.4%, followed by immediate 
addition of cells to a concentration of 1000   
cells/ml. Five hundred µl was added to the inner  
wells of a poly-HEMA-coated 48-well plate (200 
µl of 5 mg/ml poly-HEMA in 96% ethanol was 
added to the wells in advance and the wells were 
left in a 37°C incubator until the ethanol had 
evaporated and only a thin poly-HEMA-film was 
left in the wells). One ml PBS was added to the 
outer wells to minimize evaporation in the 
agarose-containing wells. The plates were 
wrapped in saran wrap, to further minimize 
evaporation, and incubated in 5% CO2 in air at 
37 °C for 14 days. The colonies were counted 
using an inverted phase contrast microscope. 
 
Cancer stem cell flow cytometry 
The cells were rinsed with PBS and incubated 
with Accutase® for 10 min after 72 hours of 
treatment with 10 µM of either PG11144 or 
PG11047. The incubation with Accutase® was 
stopped by addition of ice-cold PBS+1% FBS. 
Two hundred thousand cells from each treatment 
were transferred to test tubes kept on ice. The 
tubes were centrifuged at 600 x g at 4°C for 5 
min. The supernatant was discarded and the cells 
were washed with 5 ml ice-cold PBS+1% FBS 
followed by centrifugation at 600 x g, 4°C for 5 
min. The supernatant was discarded and 
antibodies against human CD44 and CD133 ( 
+AlexaFluor® 594) or CD29 and CD24 in 100 
µl (1:100) were added to each tube followed by 
incubation on ice on a shaker for 15 minutes. The 
cells were thereafter washed with 5 ml PBS+1% 
FBS and centrifuged, twice. The supernatant was 
discarded and the pellets were vortexed with1 ml 
PBS+1% FBS. The samples were analyzed using 
BD Accuri C6 flow cytometer, and analyzed 
with the BD CFlow®  soft ware. 
 
Statistics 
A two-tailed, unpaired student’s t-test was used 
to evaluate the significance. 
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Results 
The dose-response relationship of PG11144 
and PG11047 measured by the MTT assay 
To investigate if the basal toxicity of PG11144 
and PG11047 in normoxia and hypoxia are dose 
dependent the MTT assay was used. The yellow 
soluble MTT salt is reduced to blue formazan 
crystals by Complex I in the electron transport 
chain in the mitochondria (36). The absorbance 
of the dissolved crystals at 540 nm, is 
proportional to the magnitude of the MTT 
reduction and is therefore said to represent the 
mitochondrial activity and the number of viable 
cells in the culture. Treatment with increasing 
concentrations of PG11144, ranging from 0.01 
µM to 100 µM, resulted in a decrease of MTT 
reduction compared to control after both 48 and 
72 hours of treatment, in both normoxia and 
hypoxia (Fig. 2). Treatment with PG11047 
resulted in less toxicity. There was a small 
decrease of the MTT reduction compared to 
control   after   treatment   in hypoxia but the 
treatment did not seem to have any prominent 
effect in normoxia. The concentration used in the 
future experiments, 10 µM, was based on these 
results. 
 
The effects of PG11144 and PG11047 
treatment on cell proliferation 
The effects of PG11144 and PG11047 on the cell 
proliferation were investigated by counting cells 
in a hemocytometer after trypsinization. The 
cells were treated with 10 µM of either PG11144 
or PG11047, or grown in the absence of the 
drugs (Fig. 3). Treatment with PG11144 
decreased the cell number to a greater extent than 
treatment with PG11047 in both normoxia and 
hypoxia. PG11144 was most effective in 
normoxia with a significant decrease in cell 
number compared to control after both 48 (P ≤ 
0.01) and 72 hours (P ≤ 0.001). After 48 hours of 
treatment the cell number was 53% of control 
and after 72 hours it was 24% of control. The 
effect in hypoxia was less prominent, though yet 
significant (P ≤ 0.01) after both 48 and 72 hours  
of treatment. PG11047 treatment decreased the 
number of cells significantly compared to control
Figure 2. MTT reduction in LNCap-FGC prostate cancer cells treated with PG11144 or PG11047 in normoxia (21% O2) or 
hypoxia (1% O2). The cells were seeded in 96-well plates and the drugs were added after 24 hours to the final concentrations 
shown in the figure. After 48 (▪) and 72 hours (♦) of treatment the mitochondrial activity was determined using the MTT 
assay. The results are presented as the mean value of the MTT reduction in percent of control and the bars represents the 
standard error (n=12 from two independent experiments). 
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Figure 3. The effects of 10 µM PG11144 or PG11047 on cell proliferation of LNCap-FGC prostate cancer cells incubated in 
normoxia and hypoxia. The cells were seeded at a density of 20000 cells/cm2 and the drugs were added 24 hours after 
seeding to a final concentration of 10 µM. The cell number was determined using a hemocytometer. The results are presented 
as the mean cell number and the bars represent the standard deviation (n=6 from two independent experiments). ♦, Control; 
■, PG11144; ▲, PG11047. *, P ≤ 0.05, **, P ≤ 0.01; ***, P ≤ 0.001, compared to control. 
 
(P ≤ 0.01) after 72 hours of treatment in 
normoxia, but no effect of the treatment was seen 
in hypoxia. After 72 hours of treatment in 
normoxia the cell number was 83% of control. 
The number of untreated cells did not increase 
over time in hypoxia.  
 
Treatment with PG11144 induced cell death 
in both normoxia and hypoxia 
Treatment with PG11144 decreased the number 
of cells over time, compared to control, and it 
was therefore of interest to investigate whether 
the compound caused cell death and how it 
affected the cell cycle phase distribution. Since 
the cell number did not increase over time for 
any of the treatments in hypoxia it was also of 
interest to see if this was due to decrease in 
proliferation or if the cells were dying at the 
same rate as they were dividing. This was done 
by analyzing DNA histograms obtained from 
cells treated with 10 µM PG11144 or PG11047 
for 24, 48, and 72 hours. The number of cells in 
the different phases of the cell cycle is presented 
as percentage of the total cell number (Fig. 4). 
Dead cells are defined as those found in the sub-
G1 region. PG11144 treatment significantly 
increased the number of dead cells in the cultures 
in normoxia (P ≤ 0.01 after 72 hours compared to  
 
 
control). In hypoxia a significant increase in the 
sub-G1 region was seen after 48 hours of 
treatment (P ≤ 0.01 compared to control), but the 
difference was not significant after 72 hours of 
treatment. Cells cultured in hypoxia showed a 
higher rate of cell death in control and both 
treatments compared with cells cultured in 
normoxia. I both normoxia and hypoxia cell 
death observed in cells treated with PG11047 
was not different compared to control. 
To investigate whether the observed cell death 
after PG11144 treatment in normoxia, and for 
cells cultured in hypoxia, was apoptotic, Western 
Blot was performed to investigate the cleavage 
of poly(ADP-ribose) polymerase (PARP) and the 
expression of caspase 3, Bcl-2, and p53. Active 
caspase 3, the cleavage product of procaspase 3, 
is a critical downstream effector molecule in the 
apoptotic pathway. It cleaves other specific 
substrates involved in apoptosis, such as PARP 
(31). No distinct expression of caspase 3 or 
PARP was observed in the LNCap cell line, 
independent of treatment (data not shown). 
Proteins of the Bcl-2 family are central in the 
regulation of the mitochondrial pathway in 
apoptosis. During apoptosis they translocate to 
the outer membrane of the mitochondria where 
they change the permeability of the membrane, 
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Figure 4. The effects of treatment with PG11144 and PG11047 on cell death and cell cycle phase distribution analyzed by 
flow cytometry. LNCap-FGC prostate cancer cells were seeded and allowed to attach for 24 hours before the compounds 
were added to a final concentration of 10 µM. The cells were cultured in either normoxia (21% O2) or hypoxia (1% O2) and 
harvested at the time points shown in the figure. a) The sub-G1 region is correlated to cell death and b) the percentage of cells 
in the G1, S and G2 phases shows the cell cycle phase distribution. The results are presented as the mean values from 3 
independent cultures and the bars represent the ± SD. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001, compared to control. 
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which in turn mediates the release of cytochrome 
c, a protein that induces caspase activation (31). 
PG11144 treatment decreased the expression of 
Bcl-2 in normoxia after 72 hours of treatment, 
which indicates that apoptosis may have been 
induced. No decrease in Bcl-2 expression was 
observed in PG11047-treated cells in normoxia. 
Bcl-2 expression in hypoxia was not 
investigated. p53 is a protein that plays a key role 
at G1-S phase checkpoint transition (37). It 
regulates      cell     cycle      progression     and    
programmed cell death by monitoring DNA 
damage, nucleotide levels, and the status of the 
mitotic spindle. An increase in p53 is maintained 
by protein stabilization and leads either to 
apoptosis or G1 arrest, depending on cell type. 
No changes in p53 levels were observed for any 
of the treatments in normoxia. However 
PG11144 treatment resulted in a higher 
expression of p53 in hypoxia after 72 hours of 
treatment, while PG11047 treatment resulted in a 
prominent decrease of the protein. (Fig. 5) 
 
 
Figure 5. Western Blot analysis of protein levels in cells treated with 10 µM PG11144 (44 in the figure) or PG11047 (47 in 
the figure) in normoxia (21% O2) or hypoxia (1% O2). The compounds were added 24 hours after seeding and the cells were 
harvested at the time points shown in the figure. Homogenates equivalent to 75 000 cells were added to each well of the gels. 
The figure shows the expression of  H3K4me2, γH2Ax, active β-catenin, p53, Bcl-2, β-actin, and GAPDH and the results are 
representatives of 3-9 independent cultures from 1-3 independent experiments. 
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Tabel 1. The colony forming efficiency of LNCap-FGC prostate cancer cells in soft agar. The cells, incubated in normoxia 
(21% O2) or hypoxia (1% O2) were treated with PG11144 or PG11047 at a final concentration of 10 µM 72 hours. After 
treatment, the cells were seeded at a density of 1000 cells/ml in soft agar. The number of colonies was determined after 14 
days of incubation in normoxia. The data represents the mean ± SD from 4 independent cultures from 2 independent 
experiments.  
Normoxia 
Control  
(% of cell population) 
PG11144 
(% of cell population) 
PG11144 
(% of control) 
PG11047  
(% of cell population) 
PG11047  
(% of control) 
< 0.1 0 0 0 0 
Hypoxia 
Control  
(% of cell population) 
PG11144  
(% of cell population) 
PG11144 
 (% of control) 
PG11047  
(% of cell population) 
PG11047  
(% of control) 
20.3 ± 4.0 8.7 ± 1.6 43.1 15.0 ± 2.7 74.0 
 
 
 
 
Figure 6. Images of the colonies formed by LNCap-FGC cells in soft agar. The cells were treated for 72 hours with PG11144 
(10 µM) or PG11047 (10 µM) in normoxia and hypoxia and were thereafter seeded in soft agar. The photos were taken after 
14 days of incubation in normoxia, using an inverted phase contrast microscope. No colonies were observed after treatment 
with either of the compounds in normoxia. 
 
Cells cultured in hypoxia showed higher 
colony forming efficiency in soft agar 
compared to cells cultured in normoxia 
In the soft agar assay the ability of cells to form 
colonies, independently of attachment to a 
surface, is investigated. The ability to grow and 
divide under these conditions is said to correlate 
to more aggressive cancer cells. In this 
experiment, cells were seeded at a low density in 
soft agar after 72 hours of treatment with 10 µM 
of PG11144 or PG11047 in either normoxia or 
hypoxia. After 14 days of incubation in 
normoxia, the colonies were counted in an 
inverted phase contrast microscope (Table 1). In 
normoxia, only very small colonies were found 
in control while no colonies were seen in any of 
the treatments. Less than 1% of the untreated 
cells seeded were able to form colonies. When  
 
cells were treated in hypoxia however, the 
number of colonies formed was much higher: 
20% of the control cell population was able to 
form colonies. The colonies were also bigger 
than the ones observed after culturing in hypoxia 
(Fig. 6). Both treatments decreased the number 
of colonies formed in hypoxia, with PG11144 
being the most effective.  
 
Expression of EMT-/MET-associated proteins 
after treatment in with PG11144 or PG11047 
in normoxia or hypoxia 
Since the number of colonies formed in soft agar 
increased after treatment in hypoxia it was of 
interest to investigate if this was due to EMT. 
This was done by analyzing the expression of the 
proteins vimentin, E-cadherin, and cytokeratin 
18 by Western Blot. Vimentin is expressed by 
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cells of the mesenchymal phenotype while E-
cadherin and cytokeratin 18 are expressed by 
cells of the epithelial phenotype. The results 
(Fig. 7) showed that both vimentin and 
cytokeratin 18 were expressed at a higher level in 
cells cultured in hypoxia compared with 
normoxia after 72 hours. The increase in 
cytokeratin 18 could be seen after 48 hours. No 
expression of E-cadherin was detected (data not 
shown). No clear difference in the expression of 
vimentin and cytokeratin 18 between the 
different treatments was observed. 
 
Expression of HIF-1α in LNCap-FGC treated 
with PG11144 and PG11047 in normoxia or 
hypoxia 
Hypoxia inducible factor HIF-1 is a heterodimer 
consisting of two subunits HIF-1α and HIF-1β. 
HIF-1β is expressed by cells cultured in both 
normoxia and hypoxia while HIF-1α is rapidly 
degraded by the proteasomes when oxygen is 
present. In hypoxia, this degradation is inhibited 
and HIF-1α can form the dimer with HIF-1β. 
HIF-1α helps the cells to cope with the hypoxic 
stress by activation of oxygen-regulated genes 
(38). It is for example involved in increasing the 
glycolytic capacity, regulation of pH, and 
glucose-uptake. Therefore it was of interest to 
look for expression of HIF-1α to see if the cells 
responded to the hypoxic environment. In 
addition, HIF-1α has also been shown to play an 
important part in the development of malignancy 
and drug resistance (38). It suppresses apoptosis 
in most transformed cells, it is involved in DNA-
repair, it acts as a co-activator of the androgen 
receptor, and it is suggested to induce EMT in 
LNCap cells (39). The expression of HIF-1α was 
investigated using Western Blot. No bands were 
detected at 120 kDa, but two distinct bands were 
observed at approximately 58 and 65 kDa. The 
expression of these products was highly 
increased by PG11144-treatment in both 
normoxia and hypoxia compared to control, with 
most prominent effect in normoxia. The 
difference between the treatments seemed to 
decrease in hypoxia after 72 hours of treatment 
(Fig. 7). 
 
 
 
Figure 7. Western Blot analysis of the levels of HIF-1α, vimentin and cytokeratin 18 in cells treated with 10 µM PG11144 
(44 in the figure) or PG11047 (47 in the figure) in normoxia or hypoxia. The compounds were added 24 hours after seeding 
and the cells were harvested at the time points given in the figure. Homogenates equivalent to 75 000 cells were loaded to 
each well of the gels. The results are representatives of 3-6 independent cultures from 1-2 independent experiments. 
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The effects of treatment with PG11144 and 
PG11047 on the surface markers CD44, 
CD133, CD29 and CD24 
No expression of the stem cell associated surface 
markers CD44, CD133 and CD24 was seen in 
the LNCap-FGC cells. CD29 however was 
expressed in both normoxia and hypoxia for all 
the treatments. The experiment was performed 
twice, each time with two independent samples. 
The first time no clear difference was observed 
between normoxia and hypoxia or between the 
different treatments, and the results varied 
considerably, but the second time the expression 
of CD29 increased from 56.0% for control in 
normoxia to 82.1% for control in hypoxia 
(priamary data from flow cytometry not shown). 
The expression in PG11144-treated cells in 
normoxia was 30.2% and in hypoxia 66.7%. 
PG11047-treatment resulted in an expression of 
42.8% in normoxia and 79.1% in hypoxia. 
 
Treatment with PG11144 and PG11047 
decreased the expression of β-catenin 
β-catenin is the key nuclear effector in the 
Wnt/β-catenin signaling pathway (40). 
Imbalance in this pathway is correlated with 
deregulated growth and metastasis in cancer. It is 
suggested that it plays a role in the activation of 
EMT (41, 42) and it is also a co-activator of the 
androgen receptor (43, 44). Therefore it was of 
interest to see whether PG11144 and PG11047 
had any effect on the expression of β-catenin, 
and whether the expression of the protein 
differed in hypoxia and normoxia. This was 
evaluated using Western Blot. Treatment with 
both compounds resulted in a decrease in β-
catenin expression in both normoxia and 
hypoxia, but the effect was more prominent in 
normoxia. The decrease could be observed 
already after 48 hours of treatment (Fig. 5). 
 
γH2Ax level after PG11144 and PG11047 
treatment in hypoxia and normoxia 
The phosphorylation of the histone H2Ax 
forming γH2Ax, occurs rapidly upon DNA 
damage (38). However, the phosphorylation is 
suggested to be dependent on HIF in cells 
cultured in hypoxia (38). The level of γH2Ax in 
cells treated with PG11144 and PG11047 in 
hypoxia or normoxia was evaluated using 
Western Blot. A small increase of γH2Ax 
expression could be seen after 72 hours in cells 
treated with PG11144 in normoxia, but except 
for that no changes in the levels of the protein 
could be detected. (Fig. 5) 
 
Treatment with PG11144 seemed to reduce 
the expression of β-actin in cells cultured in 
normoxia 
When beginning the Western Blot experiments, 
β-actin was chosen as a loading control. 
However it turned out that the levels of β-actin 
were lower in all the samples treated with 
PG11144 in normoxia compared to control. No 
such decrease was seen for the same treatment in 
hypoxia. GAPDH is also a loading control 
commonly used. The levels of GAPDH also 
decreased slightly after 72 hours of treatment 
with PG11144 in normoxia. (Fig. 5) 
Treatment with PG11144 and PG11047 did 
not seem to have an impact on the 
demethylation of H3K4me2 
Previous studies have shown that PG11144 
inhibits the enzyme LSD-1 in human colorectal 
cancer (33, 45). LSD-1 demethylates the histone 
H3K4me1/me2, which leads to silencing of 
tumor suppressor genes. Thus, PG11144 
treatment has been shown to increase the level of 
H3K4me2 (33, 45). To investigate if PG11144 
had the same actions in LNCap prostate cancer 
cells the expression of H3K4me2 in whole cell 
extracts and LSD-1 in nuclear extracts was 
investigated using Western Blot. No detectable 
levels of LSD-1 were seen. The levels of 
H3K4me2 did not seem to change in treated cells 
with any of the compounds (Fig. 5) 
 
Discussion 
One of many new targets in the development of 
anti-cancer drugs is the polyamine pathway. 
Polyamines are essential for cell proliferation 
and the levels are highly up-regulated in cancer 
cells. One way to interfere with this pathway is 
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to use polyamine analogues that gain access to 
the cells by the natural polyamine transport 
system. Once inside the cells they take advantage 
of the self-regulatory mechanisms of the 
polyamine pathway, thereby depleting the levels 
of the naturally occurring polyamines putrescine, 
spermidine and spermine, which leads to 
decreased cell proliferation (15). 
     In this study, the effect of the two polyamine 
analogues PG11144 and PG11047 on the 
androgen-dependent prostate cancer cell line 
LNCap-FGC was investigated. Since most 
tumors contain oxygen-deprived areas, and these 
areas have been associated with development of 
more aggressive cancer cells, it was of interest to 
study the effects on cells cultured in both 
normoxia (21% O2) and hypoxia (1% O2). 
Hypoxia usually results in decreased cell 
proliferation and therefore the hypothesis was 
that the compounds would be less effective under 
these conditions compared to normoxia, both 
because the time required to see any result would 
be longer and because the polyamine pathway is 
down-regulated in slowly proliferating cells (17, 
18), which could make the polyamine analogues 
less effective. This turned out to be true for both 
the treatments, regarding effects on cell 
proliferation. Treatment with PG11047 did not 
have any detectable effect on the cell number in 
hypoxia, while PG11144 reduced the number of 
cells, but was still less effective than in 
normoxia. It would have been of interest to treat 
the cells for a longer time than 72 hours. 
Analysis of DNA histograms obtained by flow 
cytometry showed that treatment with PG11144 
also caused cell death in LNCap-FGC cells in 
both hypoxia and normoxia. PG11047 decreased 
the number of cells in normoxia but no cell death 
was observed indicating that the decrease was 
only due to inhibition of cell proliferation. To 
investigate if the decrease in cell proliferation 
actually was due to depleted polyamine levels, 
the intracellular polyamine contents have to be 
measured in future studies. 
     The protein expressions of the cells were 
investigated using Western Blot. Initially, β-actin 
was chosen as a loading control. Unexpectedly 
the results showed a decrease in β-actin after 72 
hours of treatment with PG11144 in normoxia 
(n=9). GAPDH was also tested as a loading 
control and yielded similar results as β-actin 
although not as pronounced. The turnover of 
actin is very slow in cells (46), thus, if the 
observation proves to be correct, PG11144 
treatment may specifically stimulate actin 
breakdown, even though the mechanisms are 
unknown. It has also been shown that polyamine 
depletion results in disappearance of actin 
filaments in the wild-type Chinese hamster ovary 
cell line CHO (47). Since it was unclear whether 
this decrease in β-actin levels was due to a 
systematic mistake or an actual degradation of β-
actin caused by the treatment we decided not to 
do any loading compensation for the other 
proteins studied, based on β-actin levels. This 
must be further investigated before we can draw 
any conclusions. The following discussion about 
the results obtained by Western Blot is based on 
the idea that the β-actin levels are reduced by 
PG11144, until proven differently. 
     The Western Blot data indicated that 72 hours 
of treatment with PG11144 in hypoxia increased 
the levels of p53 in LNCap-FGC cells. Since p53 
inhibits growth and is involved in the induction 
of apoptosis (37) this increase may suggest that 
the increased sub-G1 fraction seen when 
analyzing DNA histograms could be due to 
apoptosis. Cell death was however also observed 
after treatment with PG11144 in normoxia but no 
increase in p53 was seen. The Bcl-2 expression 
decreased though, which is also associated with 
apoptosis. In the time-laps movies obtained by 
holographic imaging, apoptosis could be seen in 
connection with mitosis (not shown). Treatment 
with PG11047 in hypoxia however, seemed to 
drastically reduce the expression of p53 
compared to control. This was unexpected since 
a decrease in p53 levels usually is correlated with 
rapid proliferation and aggressive cancer cells. 
To further investigate the mechanisms behind 
this reduction it would be of interest to 
investigate the effect on other proteins involved 
in the regulation loop of p53, such as MDM2 
which blocks the expression of p53 as well as 
promotes a rapid degradation of the protein (48, 
49). Studies also shows that hypoxia selects for 
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cells that do not express p53 (11) but if so, this 
should be expected also in control cells. 
Deregulation of wild type p53 is not a desirable 
feature of a potential cancer drug. LNCap-FGC 
cells express wild type p53 (49). 
     When studying the effect of PG11144 and 
PG11047 on the colony forming efficiency in 
soft agar only a few, very small colonies were 
seen in the untreated cultures in normoxia. 
However in hypoxia, 20.3% of the seeded, 
untreated cell population managed to form 
colonies suggesting that hypoxia increased the 
malignancy of the cells. This supported the 
hypothesis that hypoxia induces EMT (8, 13) and 
increases the number of cancer stem cells (13). 
Both PG11144 and PG11047 did decrease the 
number of colonies formed in hypoxia. Markers 
for EMT/MET were further studied by Western 
Blot. An increase in vimentin expression was 
observed in control after 72 hours in hypoxia 
which suggest that EMT was involved in the 
increased colony forming efficiency. However, 
cytokeratin 18 also increased in hypoxia 
indicating the opposite. No differences in the 
expressions of vimentin or cytokeratin 18 
between the treatments were seen. This suggests 
that there are other mechanisms involved as well. 
The effect on cancer stem cells was also studied. 
Four different cancer stem cell markers were 
studied: CD44, CD133, CD24 and CD29 (51). 
Only expression of CD29 was observed in this 
cell line as has been reported previously (51). 
CD29 or β1 integrin plays a role in cell 
attachment (52). In the first experiment 
performed no difference between hypoxia and 
normoxia or between the different treatments 
was observed. But when the study was repeated 
the number of cells expressing CD29 increased 
in hypoxia compared to normoxia and both the 
treatments reduced the number of CD29-
expressing cells, with PG11144 being the most 
effective. Since this is only based on two 
independent samples from one experiment no 
conclusions can be drawn, but it might give an 
indication that hypoxia can increase the number 
of cancer stem cells and that the PG11144 and 
PG11047 can reduce the number in both 
normoxia and hypoxia. Repeating this 
experiment would be necessary. 
     The expression of active β-catenin decreased 
after treatment with both PG11144 and 
PG11047, in both normoxia and hypoxia. Since 
β-catenin is said to be involved in metastasis and 
EMT (41) this may be an explanation to the 
decrease in the colony forming efficiency in soft 
agar and the possible decrease in the number of 
cancer stem cells. 
     HIF-1α is a protein that is rapidly degraded in 
normoxia and the levels were therefore 
investigated to see if the cells actually were 
cultured in a hypoxic environment. Another 
reason to investigate HIF-1α, is its involvement 
in the induction of EMT. No levels were seen at 
120 kDa in either hypoxia or normoxia. This 
could mean that the environment was not 
hypoxic after all, but it could also be because of 
the time points chosen for investigation of the 
HIF-1α expression. HIF-1α is highly expressed 
when the cells first come in contact with hypoxia 
to make them cope with the stressful 
environment, but the level decreases over time 
when other factors are taking over (53). It would 
have been of interest to study the expression at 
earlier time points than 48 hours. Even though no 
bands showed up at 120 kDa two strong bands 
quickly appeared at ~60 kDa. PG11144 
treatment gave much stronger bands in both 
normoxia and hypoxia. The identity of these 
bands is unknown but there are several splice 
variants of HIF-1α of sizes that may explain the 
presence of two bands around 60 kDa (54). 
     To conclude, both PG11144 and PG11047 
showed features that are desirable for anti-cancer 
drugs. Treatment with PG11144 effectively 
inhibits cell proliferation and cause cell death in 
both normoxia and hypoxia and it decreases the 
malignancy of the cells. But there might be a risk 
that it is too toxic for the cells and that it inhibit 
functions that is not unique for cancer cells but 
exists in normal cells too and therefore further 
studies of the toxicity is required. PG11047 was 
less toxic than PG11144, it significantly 
inhibited the proliferation in normoxia but it did 
not cause cell death. The decreased number of  
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colonies formed in soft agar and the decrease in 
β-catenin expression also indicates that this 
compound is also able reduce the malignancy of 
the cells. PG11047 could therefore be considered 
the most promising of the two compounds. 
However, PG11047 caused a down-regulation of 
p53 in cells cultured in hypoxia, something that 
is associated with rapid, uncontrolled cell 
proliferation. Therefore it is of great importance 
to find the mechanisms behind this. Since these 
studies were only performed in vitro, in vivo 
studies would also be of interest, especially to 
see whether the compounds can reach the 
hypoxic regions of the tumor or not. Since these 
regions lack sufficient blood supply, it requires 
that the concentration of the drug is high enough 
to be able to diffuse into these areas. Then it is 
important that this dose is not toxic to the rest of 
the body. Since cancer treatment often occurs 
over a long time it would also be interesting to 
do long-time studies with the compounds in 
vitro. 
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